Ensuring reproducible analysis results in 
SARS-CoV-2 research 

Live webinar

Since the emergence of the COVID-19 pandemic, extensive studies have continued to explore the disease pathogenesis, as well as acquired and induced immunity against the infection. With the recent development and dissemination of COVID-19 vaccinations, cellular analysis of  T and B cells has become crucial not only for patient monitoring, but also in evaluating the efficiency of immunization of candidate and established vaccines. 

Working with these rare cells can prove challenging to researchers: critically low cell frequencies, inflammatory environments, unspecific labeling, and high levels of background noise often hamper reliable analysis. In this webinar, we will introduce solutions for the efficient and reproducible analysis of these cell types in SARS-CoV-2 research.  
 

Learning objectives:

  • Importance of cellular analysis in SARS-CoV-2 research
  • Precise analysis of SARS-CoV-2–reactive T cells in PBMC or whole blood samples
  • Detection, phenotyping, and sorting of SARS-CoV-2–specific B cells

Session (choice of two dates)

May 4, 2021
Berlin, Germany (GMT+02:00) − 7:00 PM CEST
San Francisco, CA, USA (GMT-07:00) − 10:00 AM PST
New York, NY, USA (GMT-04:00) − 1:00 PM EDT

Register here

 

May 6, 2021
Berlin, Germany (GMT+02:00) − 10:00 AM CEST
London, United Kingdom (GMT+01:00) − 9:00 AM GMT
Singapore, Singapore (GMT+08:00) − 4:00 PM

Register here

 

About the presenters

Urmi Roy

  • 2018 – present: Product Manager for the flow cytometry reagent portfolio at Miltenyi Biotec
  • 2014 – 2018 PhD in Immunology at TU Braunschweig, where she specialized in mucosal immunology/gut microbiota

Lorenz Fülle

  • 2020 – present: Global Product Manager for antigen- and virus-specific T cells
  • 2013 – 2020: PhD in Immunology and Post-doctoral Fellow at the Department of Immunology & Environment, University of Bonn, Germany

Jessica Mrugala

  • 2021 – present: Junior Global Product Manager for the MACSprep Portfolio and supporting the SARS-CoV-2 T cell project at Miltenyi Biotec 
  • 2015-2021: PhD and Postdoc in Diabetes Research at the German Diabetes Center, Düsseldorf 

Cristina Conforti Andreoni

  • 2018 –present: Group Leader, Marketing Immunology, Miltenyi Biotec
  • 2015 – 2018: Global Product Manager, Myeloid Cell Products, Miltenyi Biotec
  • 2013 – 2015 Global Product Manager, Cell Culture, Miltenyi Biotec
  • 2011 – 2012 Scientific Officer, Ayoxxa
  • 2001 – 2011: BSc and MSc in Medical Biotechnology, and PhD on dendritic cells and danger signals, University  of Milan-Bicocca / A-STAR, SIgN, Singapore; Post-doctoral Fellow, A-STAR, SIgN, Singapore  on dendritic cells and Th17 cells in inflammation

Urmi Roy, Miltenyi Biotec

Lorenz Fülle, Miltenyi Biotec

Jessica Mrugala, Miltenyi Biotec

Cristina Conforti Andreoni, Miltenyi Biotec